Literature DB >> 20103648

Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1.

Yoon-Jin Lee1, Moritz Koch, Daniel Karl, Antoni X Torres-Collado, Namali T Fernando, Courtney Rothrock, Darshini Kuruppu, Sandra Ryeom, M Luisa Iruela-Arispe, Sam S Yoon.   

Abstract

Metastasis relies on angiogenesis for tumor expansion. Tumor angiogenesis is restrained by a variety of endogenous inhibitors, including thrombospondin 1 (TSP1). The principal antiangiogenic activity of TSP1 resides in a domain containing three TSP1 repeats (3TSR), and TSP1 cleavage is regulated, in part, by the metalloproteinase ADAMTS1. In this study, we examined the role of TSP1 and ADAMTS1 in controlling metastatic disease in the liver and lung. TSP1 overexpression inhibited metastatic growth of colon or renal carcinoma cells in liver but not lung. Metastatic melanoma in liver grew more rapidly in Tsp1-null mice compared with controls, whereas in lung grew similarly in Tsp1-null mice or controls. Recombinant TSP1 was cleaved more efficiently in lysates from liver than lung. ADAMTS1 inhibition by neutralizing antibody, small interfering RNA, or genetic deletion abrogated cleavage activity. To confirm that lack of cleavage of TSP1 ablated its antiangiogenic function in the lung, we generated colon cancer cells stably secreting only the 3TSR domain and found that they inhibited formation of both liver and lung metastases. Collectively, our results indicate that the antiangiogenic activity of TSP1 is differentially regulated by ADAMTS1 in the liver and lung, emphasizing the concept that regulation of angiogenesis is varied in different tissue environments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20103648      PMCID: PMC2934910          DOI: 10.1158/0008-5472.CAN-09-3094

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  The two faces of transforming growth factor beta in carcinogenesis.

Authors:  Anita B Roberts; Lalage M Wakefield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-14       Impact factor: 11.205

2.  ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2.

Authors:  Nathan V Lee; Makoto Sato; Douglas S Annis; Joseph A Loo; Lily Wu; Deane F Mosher; M Luisa Iruela-Arispe
Journal:  EMBO J       Date:  2006-11-02       Impact factor: 11.598

Review 3.  Structures of thrombospondins.

Authors:  C B Carlson; J Lawler; D F Mosher
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

4.  Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.

Authors:  Thomas Hawighorst; Hajimu Oura; Michael Streit; Lauren Janes; Lynh Nguyen; Lawrence F Brown; Guillermo Oliver; David G Jackson; Michael Detmar
Journal:  Oncogene       Date:  2002-11-14       Impact factor: 9.867

5.  Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.

Authors:  Linda S Gutierrez; Mark Suckow; Jack Lawler; Victoria A Ploplis; Francis J Castellino
Journal:  Carcinogenesis       Date:  2003-02       Impact factor: 4.944

Review 6.  Regulation of thrombospondin1 by extracellular proteases.

Authors:  M Luisa Iruela-Arispe
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

Review 7.  Tumor progression: the effects of thrombospondin-1 and -2.

Authors:  Jack Lawler; Michael Detmar
Journal:  Int J Biochem Cell Biol       Date:  2004-06       Impact factor: 5.085

Review 8.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  L Claesson-Welsh
Journal:  Biochem Soc Trans       Date:  2003-02       Impact factor: 5.407

9.  Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

Authors:  Namali T Fernando; Moritz Koch; Courtney Rothrock; Lila K Gollogly; Patricia A D'Amore; Sandra Ryeom; Sam S Yoon
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

10.  Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1.

Authors:  Naeem A Ali; Alice A Gaughan; Charles G Orosz; Chris P Baran; Sara McMaken; Yijie Wang; Timothy D Eubank; Melissa Hunter; Frank J Lichtenberger; Nicholas A Flavahan; Jack Lawler; Clay B Marsh
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

View more
  21 in total

1.  miR-365b-3p inhibits the cell proliferation and migration of human coronary artery smooth muscle cells by directly targeting ADAMTS1 in coronary atherosclerosis.

Authors:  Yunfei Qu; Ning Zhang
Journal:  Exp Ther Med       Date:  2018-09-11       Impact factor: 2.447

2.  Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers.

Authors:  Eui Jin Suh; Mohammad Humayun Kabir; Un Beom Kang; Jong Won Lee; Jonghan Yu; Dong Young Noh; Cheolju Lee
Journal:  Exp Mol Med       Date:  2012-01-31       Impact factor: 8.718

Review 3.  The roles of ADAMTS in angiogenesis and cancer.

Authors:  Yi Sun; Jintuan Huang; Zuli Yang
Journal:  Tumour Biol       Date:  2015-04-28

Review 4.  The Contribution of Angiogenesis to the Process of Metastasis.

Authors:  Diane R Bielenberg; Bruce R Zetter
Journal:  Cancer J       Date:  2015 Jul-Aug       Impact factor: 3.360

5.  Expression of ADAMTS1 and its correlation with angiogenesis in primary gastric cancer and lymph node metastasis.

Authors:  Jing Chen; Yu Zhi; Xiaojing Chang; Shuanglong Zhang; Dongqiu Dai
Journal:  Dig Dis Sci       Date:  2012-09-22       Impact factor: 3.199

6.  Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.

Authors:  Yeo-Jung Kim; Hae-June Lee; Tae-Min Kim; T S Karin Eisinger-Mathason; Alexia Y Zhang; Benjamin Schmidt; Daniel L Karl; Michael S Nakazawa; Peter J Park; M Celeste Simon; Sam S Yoon
Journal:  Int J Cancer       Date:  2012-06-26       Impact factor: 7.396

Review 7.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

8.  hHSS1: a novel secreted factor and suppressor of glioma growth located at chromosome 19q13.33.

Authors:  Katiana S Junes-Gill; Timothy K Gallaher; Zoya Gluzman-Poltorak; Joseph D Miller; Christopher J Wheeler; Xuemo Fan; Lena A Basile
Journal:  J Neurooncol       Date:  2010-07-31       Impact factor: 4.130

9.  A systems view of epithelial-mesenchymal transition signaling states.

Authors:  Stuart Thomson; Filippo Petti; Izabela Sujka-Kwok; Peter Mercado; James Bean; Melissa Monaghan; Sean L Seymour; Gretchen M Argast; David M Epstein; John D Haley
Journal:  Clin Exp Metastasis       Date:  2010-12-31       Impact factor: 5.150

10.  Emerging Roles of ADAMTSs in Angiogenesis and Cancer.

Authors:  Saran Kumar; Nithya Rao; Ruowen Ge
Journal:  Cancers (Basel)       Date:  2012-11-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.